Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorOxford University-
Autor(es): dc.contributorSiena University-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorP95 Epidemiology & Pharmacovigilance-
Autor(es): dc.contributorCity of Botucatu-
Autor(es): dc.contributorInternational Vaccine Institute (IVI)-
Autor(es): dc.creatorClemens, Sue Ann Costa-
Autor(es): dc.creatorFortaleza, Carlos Magno Castelo Branco-
Autor(es): dc.creatorCrowe, Madeleine-
Autor(es): dc.creatorPollard, Andrew-
Autor(es): dc.creatorTasca, Karen Ingrid-
Autor(es): dc.creatorGrotto, Rejane Maria Tommasini-
Autor(es): dc.creatorMartins, Marcelo Roberto-
Autor(es): dc.creatorSpadaro, André Gasparini-
Autor(es): dc.creatorBarretti, Pasqual-
Autor(es): dc.creatorVerstraeten, Tom-
Autor(es): dc.creatorClemens, Ralf-
Data de aceite: dc.date.accessioned2025-08-21T16:16:52Z-
Data de disponibilização: dc.date.available2025-08-21T16:16:52Z-
Data de envio: dc.date.issued2023-03-02-
Data de envio: dc.date.issued2023-03-02-
Data de envio: dc.date.issued2021-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2022.08.026-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/242222-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/242222-
Descrição: dc.descriptionIntroduction: Brazil has been at the core of the COVID-19 pandemic, with the second-highest death toll worldwide. A mass vaccination campaign was initiated on May 16th, 2021, in Botucatu, Brazil, where two doses of ChadOx1-nCoV19 were offered 12 weeks apart to all 18–60- year-olds. This context offers a unique opportunity to study the vaccine safety during a mass campaign. Methods: The first and second doses of the vaccine were administered in May and August 2021, respectively. Emergency room (ER) and hospitalization records were obtained from the Hospital das Clínicas da Faculdade de Medicina de Botucatu for six weeks before and six weeks after the first and second doses, from 4 April to 19 September 2021. Diagnoses with COVID-19-related ICD codes were excluded to distinguish any trends resulting from the COVID-19 pandemic. ER and hospital visits during the two time periods were compared, including an ICD code comparison, to identify any changes in disease distributions. Data were scanned for a defined list of Adverse Events of Special Interest (AESIs), as presented by the Safety Platform for Emergency Vaccines. Results and discussion: A total of 77,683 and 74,051 subjects received dose 1 and dose 2 of ChadOx1-nCoV19, respectively. Vaccination was well tolerated and not associated with any major safety concerns. Increases in ER visits 1 week following both doses were primarily seen in ICD codes related to non-serious side effects of the vaccine, including vaccination site pain and other local events. The neurological AESIs identified (2 of 3 cases of multiple sclerosis) were relapses of a pre-existing condition. One potentially serious hospitalization event for Bell's palsy had onset before vaccination with dose 1, in a patient who also had a viral infection of the central nervous system. There was no myocarditis, pericarditis cases, or vaccine-related increases in thromboembolic events.-
Descrição: dc.descriptionDepartment of Pediatrics Oxford University-
Descrição: dc.descriptionInstitute for Global Health Siena University-
Descrição: dc.descriptionDepartment of Infectious Diseases Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionP95 Epidemiology & Pharmacovigilance-
Descrição: dc.descriptionDepartment of Biotechnology Faculty of Agronomical Sciences São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionDivision of Informatics Botucatu Medical Hospital Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionBotucatu Health Department City of Botucatu-
Descrição: dc.descriptionDepartment of Clinical Medicine Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionInternational Vaccine Institute (IVI)-
Descrição: dc.descriptionDepartment of Infectious Diseases Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionDepartment of Biotechnology Faculty of Agronomical Sciences São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionDivision of Informatics Botucatu Medical Hospital Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Descrição: dc.descriptionDepartment of Clinical Medicine Botucatu Medical School São Paulo State University (UNESP), São Paulo State-
Idioma: dc.languageen-
Relação: dc.relationVaccine-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAdverse events-
Palavras-chave: dc.subjectChadOx1-nCoV19-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectImmunisation-
Palavras-chave: dc.subjectVaccine safety-
Título: dc.titleSafety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.